Genomic Health Focuses on Oncotype DX Tests for DCIS and Colon Cancer for Future Growth
August 10, 2011
Genomic Health Focuses on Oncotype DX Tests for DCIS and Colon Cancer for Future Growth
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genomic Health Partners with OncoMed to Grow Companion Dx, NGS Reach
May 9, 2012 / Pharmacogenomics Reporter - Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
November 10, 2010 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter - Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 8, 2012 / Pharmacogenomics Reporter - Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter